Browsing by Author Stroiakovski, Daniel

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 3 of 3
Issue DateTitleAuthor(s)Citation
2015Improved overall survival in melanoma with combined dabrafenib and trametinibLong, Georgina; Chiarion-Sileni, Vanna; Dummer, R; et al, Various; Grange, Florent; Karaszewska, Boguslawa; Lichinitser, Michael; Mackiewicz, Andrzej; Mortier, Laurent; Robert, Caroline; Rutkowski, Piotr; Schachter, Jacob; Stroiakovski, Daniel; Central Clinical School: The Sydney Cancer CentreImproved overall survival in melanoma with combined dabrafenib and trametinib, New England Journal of Medicine, vol.372, 1, 2015,pp 30-39
2010Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 studyPavlakis, Nick; Crino, Lucio; Dansin, Eric; Garrido, Pilar; Griesinger, Frank; Laskin, Janessa; Stroiakovski, Daniel; Thatcher, N; Tsai, Chun-Ming; Wu, Yi-long; Zhou, Caicun; Northern Clinical School: MedicineSafety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study, Lancet Oncology, vol.11, 8,pp 733-740
2017Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trialsLong, Georgina; Chiarion-Sileni, Vanna; Dutriaux, Caroline; et al, Various; Garbe, Claus; Hauschild, Axel; Karaszewska, Boguslawa; Levchenko, Evgeny; Schachter, Jacob; Schadendorf, D; Stroiakovski, Daniel; Northern Clinical School: MedicineThree-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials, European Journal of Cancer, vol.82, N/A, 2017,pp 45-55